Radiologic Observations in Severe Neonatal Respiratory Distress Syndrome Treated with the Isolated Phospholipid Fraction of Natural Surfactant

1987 ◽  
Vol 28 (4) ◽  
pp. 389-394 ◽  
Author(s):  
W. Mortensson ◽  
G. Noack ◽  
T. Curstedt ◽  
P. Herin ◽  
B. Robertson

Ten newborn babies with severe respiratory distress syndrome, all dependent on artificial ventilation, were treated via the airways with the isolated phospholipid fraction of bovine or porcine surfactant. After treatment with surfactant at a median age of 10.5h, there was in all patients a striking improvement of lung aeration in chest films, with a decrease in parenchymal fluid retention and in distension of bronchioli. These radiologic findings were associated with a dramatic improvement of oxygenation and a significant reduction of the right-to-left shunt. In spite of the rapid therapeutic response, four patients died from cerebral hemorrhage. One of the surviving patients developed bronchopulmonary dysplasia. Our findings document efficacy of this new surfactant preparation in the neonatal respiratory distress syndrome, but the long-term effects need to be further tested in randomized clinical trials.

PEDIATRICS ◽  
1988 ◽  
Vol 82 (5) ◽  
pp. 683-691
Author(s):  

In a randomized multicenter trial, involving the collaboration of eight European neonatal intensive care units, the efficacy of replacement therapy with a new surfactant preparation (Curosurf) was tested in 146 patients with severe neonatal respiratory distress syndrome. Criteria for entry included birth weight 700 to 2,000 g, age when treated two to 15 hours, and requirement of artificial ventilation with Fio2 ≥ 0.6. The babies were treated with a single large dose of surfactant (200 mg/kg) at a median age of nine hours (range two to 15 hours). Average Fio2 before treatment was the same (0.80) for both surfactant-treated patients and control patients. Babies receiving surfactant showed, within five minutes, a dramatic improvement of oxygenation as reflected by a nearly threefold increase of the Pao2/Fio2 ratio. Six hours after randomization, the Pao2/Fio2 ratio still showed a 98% improvement in surfactant-treated patients compared with controls (P < .001), and statistically significant differences in favor of the treated babies persisted until 48 hours after randomization, when surviving control infants began to recover. Treatment with surfactant decreased neonatal (≤28 days) mortality from 51% to 31% (P < .05). Compared with control babies, the surfactant-treated group also had a decreased incidence of pulmonary interstitial emphysema (23% v 39%; P < .05) and pneumothorax (18% v 35%; P < .05). The percentage of survivors without bronchopulmonary dysplasia in the treated group was more than twice that of the control group (55% v 26%; P < .001). Treatment with this surfactant appears to effectively improve lung function and short-term outcome in infants with severe respiratory distress syndrome.


2019 ◽  
Vol 134 ◽  
pp. 19-25 ◽  
Author(s):  
Beena G. Sood ◽  
Josef Cortez ◽  
Madhuri Kolli ◽  
Amit Sharma ◽  
Virginia Delaney-Black ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document